Home » Stocks » EIDX

Eidos Therapeutics, Inc. (EIDX)

Stock Price: $122.21 USD -6.23 (-4.85%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 4.75B
Revenue (ttm) 127,000
Net Income (ttm) -100.83M
Shares Out 38.39M
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $122.21
Previous Close $128.44
Change ($) -6.23
Change (%) -4.85%
Day's Open -
Day's Range 116.77 - 128.49
Day's Volume 0
52-Week Range 38.03 - 131.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. ("Eidos") (NASDAQ GS: EIDX) regarding possible breaches of fid...

PRNewsWire - 2 months ago

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violati...

GlobeNewsWire - 2 months ago

SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provide...

PRNewsWire - 3 months ago

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

Business Wire - 3 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Eidos Th...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against clinical-...

PRNewsWire - 3 months ago

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eidos Therapeutics, Inc. ("EID...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Eidos Therapeutics, Inc. (NASDAQ: EIDX) to BridgeBio Pharma, Inc. is fair t...

The Motley Fool - 3 months ago

BridgeBio announced plans to fully acquire the biotech.

Other stocks mentioned: BBIO
Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...

Other stocks mentioned: BBIO
Invezz - 3 months ago

BridgeBio Pharma Inc (NASDAQ: BBIO) said on Monday that it will increase its stake in Eidos Therapeutics Inc (NASDAQ: EIDX) by 36.3% in a cash deal that is valued at £134.95 million (aggregate...

Other stocks mentioned: BBIO
PRNewsWire - 3 months ago

SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Eidos Therapeutics, Inc. ("Eidos" or the...

Market Watch - 3 months ago

BridgeBio Pharma Inc. BBIO, announced Monday an agreement to buy Eidos Therapeutics Inc. EIDX, -0.30% in a deal that values Eidos at about $2.83 billion. Eidos's stock is currently halted for ...

Other stocks mentioned: BBIO
GlobeNewsWire - 3 months ago

BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own

Other stocks mentioned: BBIO
GlobeNewsWire - 5 months ago

SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in...

GlobeNewsWire - 5 months ago

SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the second quarter ended June 30, 2020 and provided...

Zacks Investment Research - 6 months ago

Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2020 and provided ...

GuruFocus - 9 months ago

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

Other stocks mentioned: AXSM, CCXI, DXCM, ENPH
Zacks Investment Research - 10 months ago

Eidos Therapeutics (EIDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Motley Fool - 1 year ago

Helping people stricken with illness can be richly rewarding in more ways than one.

Other stocks mentioned: ARQL, ARWR, GH, KOD, MEDP, NEO, NVRO, THC, ZTS
Benzinga - 1 year ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, HRTX, LGND, PRTK, PTE, VKTX, XON, ZIOP
The Motley Fool - 1 year ago

It’s David vs. Goliath.

Zacks Investment Research - 1 year ago

Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 1 year ago

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

The Motley Fool - 1 year ago

The sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.

Other stocks mentioned: AKCA, ALNY, IONS
The Motley Fool - 1 year ago

BridgeBio announced this week that it had terminated its effort to acquire the remaining stake in subsidiary Eidos Therapeutics. What does this mean for Eidos shareholders?

Other stocks mentioned: BBIO
GlobeNewsWire - 1 year ago

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet...

GlobeNewsWire - 1 year ago

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference...

The Motley Fool - 1 year ago

Can their share prices continue to climb?

Other stocks mentioned: STOK
24/7 Wall Street - 1 year ago

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower pr...

Other stocks mentioned: AKCA, AMAG, LGND, MNKD, MRNA, PRTK, VKTX
GuruFocus - 1 year ago

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Other stocks mentioned: AGNC, DISCA, XON

About EIDX

Eidos Therapeutics, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Industry
Biotechnology
IPO Date
Jun 20, 2018
CEO
Neil Kumar
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
EIDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for EIDX stock is "Hold." The 12-month stock price forecast is 78.71, which is a decrease of -35.59% from the latest price.

Price Target
$78.71
(-35.59% downside)
Analyst Consensus: Hold